JP2023551943A5 - - Google Patents
Info
- Publication number
- JP2023551943A5 JP2023551943A5 JP2023533801A JP2023533801A JP2023551943A5 JP 2023551943 A5 JP2023551943 A5 JP 2023551943A5 JP 2023533801 A JP2023533801 A JP 2023533801A JP 2023533801 A JP2023533801 A JP 2023533801A JP 2023551943 A5 JP2023551943 A5 JP 2023551943A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- compound
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121508P | 2020-12-04 | 2020-12-04 | |
| US202063121513P | 2020-12-04 | 2020-12-04 | |
| US63/121,513 | 2020-12-04 | ||
| US63/121,508 | 2020-12-04 | ||
| PCT/IB2021/061268 WO2022118264A1 (en) | 2020-12-04 | 2021-12-03 | Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551943A JP2023551943A (ja) | 2023-12-13 |
| JP2023551943A5 true JP2023551943A5 (enExample) | 2024-12-10 |
Family
ID=78844691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533801A Pending JP2023551943A (ja) | 2020-12-04 | 2021-12-03 | うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240041853A1 (enExample) |
| EP (1) | EP4255419A1 (enExample) |
| JP (1) | JP2023551943A (enExample) |
| KR (1) | KR20230116865A (enExample) |
| AU (1) | AU2021390209A1 (enExample) |
| CA (1) | CA3203144A1 (enExample) |
| IL (1) | IL303357A (enExample) |
| MX (1) | MX2023006567A (enExample) |
| TW (1) | TW202237103A (enExample) |
| WO (1) | WO2022118264A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119654149A (zh) * | 2022-06-02 | 2025-03-18 | 诺华股份有限公司 | 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法 |
| WO2025120013A1 (en) * | 2023-12-06 | 2025-06-12 | Novartis Ag | Compositions and methods for treating depression disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| US9540324B2 (en) * | 2013-09-26 | 2017-01-10 | Luc Therapeutics, Inc. | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| CA2970958A1 (en) * | 2014-12-23 | 2016-06-30 | Cerecor, Inc. | Compounds, compositions and methods |
| MX2018004256A (es) * | 2015-10-14 | 2018-05-16 | Squibb Bristol Myers Co | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. |
| CA3001894A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
-
2021
- 2021-12-03 EP EP21824044.8A patent/EP4255419A1/en not_active Withdrawn
- 2021-12-03 AU AU2021390209A patent/AU2021390209A1/en not_active Abandoned
- 2021-12-03 KR KR1020237021993A patent/KR20230116865A/ko active Pending
- 2021-12-03 MX MX2023006567A patent/MX2023006567A/es unknown
- 2021-12-03 US US18/255,423 patent/US20240041853A1/en not_active Abandoned
- 2021-12-03 JP JP2023533801A patent/JP2023551943A/ja active Pending
- 2021-12-03 CA CA3203144A patent/CA3203144A1/en active Pending
- 2021-12-03 TW TW110145295A patent/TW202237103A/zh unknown
- 2021-12-03 IL IL303357A patent/IL303357A/en unknown
- 2021-12-03 WO PCT/IB2021/061268 patent/WO2022118264A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541432A5 (enExample) | ||
| JP2009530385A5 (ja) | うつ病の治療のためのケタミンの投与 | |
| JP2015526458A5 (enExample) | ||
| EP4233861A3 (en) | Compositions for treatment of essential tremor | |
| JP2018083842A (ja) | パーキンソン病の処置に伴う運動不全及び運動障害副作用の処置 | |
| JP2021527050A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| RU2018121615A (ru) | Модуляторы активности комплемента | |
| JP2017501154A5 (enExample) | ||
| EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
| BR112022013264A2 (pt) | Combinação de formas de dosagem oral sólida de decitabina e cedazuridina | |
| JP2022554276A5 (enExample) | ||
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| JP2025148449A5 (enExample) | ||
| JP2021004249A5 (enExample) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2021535163A5 (enExample) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2023544409A5 (enExample) | ||
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| JP2005529152A5 (enExample) | ||
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| RU2018144248A (ru) | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта | |
| Thongim et al. | Contemporary trends in dental local anaesthesia: a review of literature | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. |